Division of Cardiac Electrophysiology at the University of California San Diego Health System, La Jolla, California, USA.
A. T. Still University School of Osteopathic Medicine, Mesa, Arizona, USA.
Clin Cardiol. 2023 Dec;46(12):1488-1494. doi: 10.1002/clc.24137. Epub 2023 Aug 25.
Catheter ablation improves outcomes in symptomatic atrial fibrillation (AF) patients. However, its safety and efficacy in the very elderly (≥80 years old) is not well described.
Ablation of AF in the very elderly is safe and effective.
We performed a retrospective study of all patients who underwent catheter ablation enrolled in the University of California, San Diego AF Ablation Registry. The primary outcome was freedom from atrial arrhythmias on or off antiarrhythmic drugs (AADs).
Of 847 patients, 42 (5.0%) were 80 years of age or greater with a median age of 81.5 (80-82.3) and 805 (95.0%) were less than 80 years of age with a median age of 64.4 (57.6-70.2). Among those who were ≥80 years old, 29 were undergoing de novo ablation (69.0%), whereas in the younger cohort, 518 (64.5%) were undergoing de novo ablation (p = .548). There were no statistically significant differences in fluoroscopy (p = .406) or total procedure times (p = .076), AAD use (p = .611), or procedural complications (p = .500) between groups. After multivariable adjustment, there were no statistically significant differences in recurrence of any atrial arrhythmias on or off AAD (adjusted hazard ratio [AHR]: 0.75; 95% confidence interval [CI]: 0.45-1.23; p = .252), all-cause hospitalizations (AHR: 0.86; 95% CI: 0.46-1.60; p = .626), or all-cause mortality (AHR: 4.48; 95% CI: 0.59-34.07; p = .147) between the very elderly and the younger cohort.
In this registry analysis, catheter ablation of AF appears similarly effective and safe in patients 80 years or older when compared to a younger cohort.
导管消融可改善有症状的心房颤动(AF)患者的预后。然而,其在非常高龄(≥80 岁)患者中的安全性和疗效尚不清楚。
高龄患者的 AF 消融是安全有效的。
我们对所有在加利福尼亚大学圣地亚哥房颤消融登记处接受导管消融的患者进行了回顾性研究。主要结局是停用或不停用抗心律失常药物(AAD)时无房性心律失常。
847 例患者中,42 例(5.0%)年龄≥80 岁,中位年龄 81.5(80-82.3)岁,805 例(95.0%)年龄<80 岁,中位年龄 64.4(57.6-70.2)岁。≥80 岁的患者中,29 例为初次消融(69.0%),而在年龄较小的患者中,518 例(64.5%)为初次消融(p=0.548)。两组间透视时间(p=0.406)或总手术时间(p=0.076)、AAD 使用(p=0.611)或手术并发症(p=0.500)无统计学差异。多变量调整后,两组间任何 AAD 或不停用 AAD 时房性心律失常的复发率(调整后的危险比 [AHR]:0.75;95%置信区间 [CI]:0.45-1.23;p=0.252)、全因住院率(AHR:0.86;95%CI:0.46-1.60;p=0.626)或全因死亡率(AHR:4.48;95%CI:0.59-34.07;p=0.147)无统计学差异。
在这项登记分析中,与年轻队列相比,80 岁或以上患者的 AF 导管消融在疗效和安全性方面似乎相似。